Vascularized composite allotransplantation (VCA) involves immunologically heterogeneous tissues and is associated with high rates of acute rejection (AR), particularly due to the immunogenicity of the skin. This study assessed biomarkers to monitor AR in a recipient of full-face and bilateral hand transplantation. Over 4.6 years postoperatively, we analyzed serial blood and tissue samples, including donor-derived cell-free DNA (dd-cfDNA) in plasma, recipient DNA in allograft biopsies using short tandem repeat (STR) analysis, lymphocyte subsets via flow cytometry, and level of angiotensin II type 1 receptor antibodies (AT1R-Abs). dd-cfDNA and STR showed trends toward elevated recipient signal during acute rejection, though differences were not statistically significant. CD8+ T-cell percentages increased before AR onset, suggesting potential as a prognostic biomarker. AT1R-Ab levels did not differ significantly between AR and non-rejection episodes, possibly due to prophylactic immune cell depletion. While dd-cfDNA and STR levels correlate with rejection episodes and reflect key cellular events within graft tissue, CD8+ T-cell count remains the most robust prognostic biomarker for predicting the onset of cytotoxicity in this patient. These findings highlight the importance of further longitudinal, multi-patient studies to validate emerging biomarkers and improve rejection monitoring strategies in VCA.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of New York University Grossman School of Medicine gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript